Company Overview and News

Fromageries BEL : Projet de transformation

2018-09-20 globenewswire
Bel est engagé depuis 2015 dans un plan de croissance visant à développer ses marques à l'international tant sur son marché historique fromager et laitier que sur le segment porteur du snacking sain.

Fromageries BEL : Half-Year 2018 Results

2018-07-27 globenewswire
Meeting July 26, 2018, the Board of Directors approved the interim consolidated financial statements as of June 30, 2018 and the auditor's limited review report was issued.

Fromageries BEL : Résultats du 1er semestre 2018

2018-07-27 globenewswire
Au cours de sa séance du 26 juillet 2018, le Conseil d'administration a arrêté les comptes consolidés semestriels résumés au 30 juin 2018 et le rapport d'audit des commissaires aux comptes a été émis sans réserves.

Fromageries BEL : Communiqué Assemblée Générale 2018

2018-05-15 globenewswire
Les actionnaires de Fromageries Bel, réunis en Assemblée Générale le 14 mai 2018, ont approuvé l'ensemble des résolutions soumises à leur vote.

Fromageries BEL :Information financière du 1er trimestre Chiffre d'affaires

2018-05-14 globenewswire
Les montants sont exprimés en millions d'euros et arrondis au million le plus proche. Les ratios et écarts sont calculés à partir des montants sous- jacents et non à partir des montants arrondis.

Fromageries BEL :First-quarter financial information Sales

2018-05-14 globenewswire
Amounts are expressed in millions of euros and rounded off to the nearest million. Ratios and variances are calculated based on underlying amounts, not rounded off amounts.

Fromageries BEL : Document de référence 2017 et AGM du 14 mai 2018

2018-04-04 globenewswire
Modalités de mise à disposition du document de référence 2017, du descriptif du programme de rachat d'actions et des documents préparatoires à l'assemblée générale mixte du Lundi 14 mai 2018

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...